Based only on the facts in our directory. The right pick still depends on the job you need done.
Lower starting price
Not comparable
Not comparable: Artera does not list a price
Free plan
Tie
Neither has one
Higher rating
Artera
4.4 against 4.3
Same job?
Yes
Both are Healthcare AI tools
Side by side
Compared on
Artera
PathAI
Our rating
4.4Better
4.3
Starts at
Not listed
Not listed
Free plan
No
No
Category
Healthcare AI
Healthcare AI
Plans
See pricing
See pricing
Key features
Multimodal AI trained on digitized biopsy images paired with clinical data
FDA De Novo authorization for the ArteraAI Prostate Test
FDA clearance for ArteraAI Breast digital pathology risk stratification
Results delivered in as little as two days after sample submission
Inclusion in National Comprehensive Cancer Network (NCCN) treatment guidelines
AISight Dx analyzes digital pathology slide images to assist diagnosis
FDA 510(k) clearance for primary diagnosis in clinical settings, June 2025
Predetermined Change Control Plan allows faster future software updates
Expanded Labcorp collaboration deploying nationwide as of February 2026
FDA Breakthrough Device Designation for PathAssist Derm dermatopathology tool
Pros
Regulatory clearance (FDA De Novo, NCCN guideline inclusion) beyond most AI health startups
Published clinical evidence showing improved outcome prediction versus existing risk models
Adopted by a meaningful share of US prostate cancer clinicians already
Genuine FDA clearance for primary diagnosis, not just an assistive tool
Predetermined Change Control Plan speeds up future regulatory-approved updates
National-scale deployment through Labcorp validates real clinical trust
Cons
Not a self-serve software product; access runs through labs, clinicians, and insurance billing
Pricing is not public and varies by payer and region
Limited to prostate and breast cancer currently, not a general oncology platform
Enterprise quote-based pricing requires a sales conversation, no published rates
Built specifically for pathology labs, not applicable to other clinical specialties
Regulatory-cleared medical device status means slower iteration than software-only tools
Company
Artera, founded 2021
PathAI, founded 2016
Prices come from each vendor's pricing page, last checked 20260802. Check the vendor before you buy.
FAQ
Questions people ask
Is Artera better than PathAI?
In our reviews Artera scores 4.4 and PathAI scores 4.3. The better pick depends on the job. Artera: FDA-cleared multimodal AI that reads biopsy images and clinical data to guide cancer therapy decisions. PathAI: First AI pathology platform FDA-cleared for primary diagnosis, now deployed nationwide via Labcorp.
Artera
PathAI
